Company intelligence / Profile preview

AVAX Technologies, Inc.

Philadelphia, Pennsylvania, United Statesen.wikipedia.org ↗

Ownership: Private
Employees: ~50
Development stage: Phase 3

Overview

MVax has shown promising efficacy in melanoma with a five-year OS rate of approximately 44% and response rates around one-third; its pivotal trial is ongoing but enrollment was suspended due to funding issues. OVax demonstrated encouraging safety and survival outcomes in advanced ovarian cancer patients resistant to standard chemotherapy—median survival reached nearly two years without significant toxicity. Both programs leverage AVAX’s autologous vaccine platform and have received Orphan Drug Status.[4][5][8]

Therapeutic areas: Oncology
Modalities: Autologous cell vaccinesTherapeutic vaccines
Industry: Biotech

Drug pipeline

5 assets

M-Vax

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on AVAX Technologies, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVAX Technologies, Inc..

Explore the full profile